BeOne Medicines AG (FRA:49BA)

Market Cap	32.50B
Revenue (ttm)	4.26B
Net Income (ttm)	28.13M
Shares Out	n/a
EPS (ttm)	0.25
PE Ratio	1,155.71
Forward PE	76.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	17
Open	292.00
Previous Close	292.00
Day's Range	290.00 - 296.00
52-Week Range	166.00 - 322.00
Beta	n/a
RSI	52.85
Earnings Date	Mar 27, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 49BA

Financial Performance

In 2024, BeOne Medicines AG's revenue was 27.81 billion, an increase of 59.51% compared to the previous year's 17.43 billion. Losses were -4.71 billion, -24.72% less than in 2023.

Financial numbers in CNY